Your Health, We Care
Release date: 2026-04-07 14:29:10 Recommended: 11
Belumosudil is a prescription medicine specifically indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients aged 12 years and older, who have failed at least two prior systemic therapies. Its uniqueness lies in its mechanism of action: belumosudil is the only approved therapy for cGVHD that directly blocks the ROCK2 pathway in the body.
By precisely inhibiting the overactivation of ROCK2, belumosudil helps rebalance the immune system: it reduces harmful cells and molecules that drive inflammation and fibrosis, while restoring protective factors that maintain immune homeostasis. This distinct mechanism means that belumosudil may still offer an effective treatment option for patients who do not respond well to other agents such as immunosuppressants (e.g., corticosteroids).
In clinical studies, belumosudil has demonstrated improvements across a broad spectrum of patients with cGVHD, including those with mild, moderate, and severe disease, as well as those with involvement of one or more organs. It represents a novel therapeutic approach distinct from traditional immunosuppression.
Chronic graft-versus-host disease is a serious complication that may occur following hematopoietic stem cell transplantation. When donor stem cells enter the body, they may recognize the recipient’s own cells and organs as foreign threats and launch an immune attack, leading to cGVHD.
The core abnormality of this disease is immune imbalance: certain cells and molecules are excessively elevated, while others are severely deficient. This imbalance triggers two key pathological processes: inflammation and fibrosis. Inflammation is the body’s protective swelling response, but persistent inflammation causes organ damage. Fibrosis refers to the excessive formation of scar tissue, which stiffens organs and gradually impairs their normal function.
cGVHD can affect multiple sites including the skin, eyes, mouth, joints, muscles, gastrointestinal tract, liver, lungs, and esophagus. Common symptoms include rash, skin discoloration, skin thickening, chronic cough, shortness of breath, joint stiffness, nausea and vomiting, diarrhea, dry eyes, dysphagia, and persistent fatigue. Beyond physical impairment, cGVHD severely reduces patients’ ability to perform daily activities and their quality of life.
Many physiological processes in the human body rely on so-called "signaling pathways" — a series of ordered reactions between cells and molecules. One such pathway, known as ROCK2, plays a central role in the development and progression of cGVHD.
In healthy individuals, the ROCK2 pathway maintains moderate activity to help preserve immune balance. However, in patients with cGVHD, this pathway becomes hyperactivated. This overactivation directly leads to two major changes: on the one hand, the number of cells and molecules that suppress excessive immune responses and maintain system balance decreases; on the other hand, cells and molecules that promote inflammation and fibrosis increase sharply.
The end result is a complete breakdown of immune homeostasis, leaving the body in a state of persistent inflammation and fibrosis. Understanding the role of the ROCK2 pathway is critical for the development of targeted therapies, as interventions targeting this pathway can fundamentally reset immune function rather than merely alleviating superficial symptoms.
